Forschung Gottfried Schatz Forschungszentrum

Research focus: Precision medicine

PI: Karin Kornmüller

Focus: The Nanomedicine Lab is focusing on the design and structural characterization of nanoparticles as natural or biomimetic nanocarriers for biological molecules and new drugs. The main focus of our research is on molecular assemblies of lipids and proteins to target specific cell types, tissues or biological barriers. The aims are addressed through a combination of innovative technologies in nanoparticle synthesis, structural biology and nanometrology.

Network: The Nanomedicine Research Team is nationally and internationally very well connected through short- and long term cooperation projects. Representative examples are scientific collaborations with partners at large scale infrastructure facilities like ILL, France and Synchrotron Trieste, Italy, but also close industrial relationships as translational settings. We are members in EU projects and in international networks. Close cooperation across Graz Universities and between Graz research groups are very well established. Internal collaboration involves the Division of Cell Biology, Histology and Embryology (Gerd Leitinger) and research groups from Molecular Biology and Biochemistry. Intensive collaborations exist with the Nano Optics Group of Ulrich Hohenester (Institute of Physics, Uni Graz), with David Clases (Nano Micro Lab, Institute of Chemistry, Uni Graz) and with FELMI-ZFE (Electron Microscopy and Nanoanalysis, TUG, Harald Fitzek).

Projects

LIPOTRACE: Tracking and Characterization of Lipid Nanoparticles by coupling Optofluidics and Mass Spectrometry

  • The FFG project LIPOTRACE is developing a groundbraking analytical platform to track and analyze nanoparticles by coupling the Opto-Fluidic Force Induction (OF2i®) technology with high-resolution mass spectrometry (ESI-HRMS). This innovative approach enables the simultaneous characterization of physical parameters (dynamic size distribution) and the chemical composition of individual lipid particles. Our research focuses on two main applications: improving the safety and efficacy of pharmaceutical drug carriers like LNPs, and advancing cardiovascular research by characterizing specific, disease-relevant subclasses of Low Density Lipoprotein (LDL).
  • Project duration: 2026-2028
  • Project partners: JOANNEUM RESEARCH Forschungsgesellschaft mbH, BRAVE Analytics GmbH

AAMLA: Apolipoprotein AI (apo-AI) Mimetic Peptide Lipid Assemblies

  • Aim of the project is to determine the structural and dynamic properties of artificially produced high density lipoprotein (HDL) nanoparticles and to correlate them with their biological behavior. These nanoparticles have anti-inflammatory and anti-oxidative properties and are proposed as a new class of therapeutics. Furthermore, we are investigating how oxidized lipids, which are significantly involved in disease progression, influence the structure and functionality of our nanoparticles.
  • Project duration: 2021-2026
  • Funded by FWF, ANR
  • Collaboration partners: Gunther Marsche (OLRC/MUG, Austria), Mounir Tarek (LPCT, Université Lorraine, France), Burkhard Bechinger (UNISTRA, Université Strasbourg, France).

LOGOS-TBI: Light-controlled organic semiconductor 3D-structure implants for improved regeneration after traumatic brain injury

  • We explore a fundamentally new concept to improve functional recovery after brain injuries. Nanostructured organic implants contain a photoactive layer that converts light pulses into surface charging. Thus, light-stimulation can trigger action potentials in attached neurons. This approach aims to promote neuronal networking, improve connectivity and enhance regeneration of injured brain tissue. The study interconnects the expertise of various disciplines and facilities: structural biology and nanomedicine, biophysics, electrical engineering, neuroscience and experimental neurotraumatology.
  • Duration: 2019-2024
  • Funded by: FWF Zukunftskolleg
  • Project partners: Muammer Ücal (Research Unit for Experimental Neurotraumatology, Med Uni Graz), Susanne Scherübel-Posch (Medical Physics and Biophysics, GSRC, Med Uni Graz), Theresa Rienmüller (TUG), Rainer Schindl (Medical Physics and Biophysics, GSRC, Med Uni Graz), Vedran Đerek (Department of Physics, Faculty of Science, University of Zagreb), Eric Głowacki (CEITEC, Brno University of Technology, Czech Republic).

STRUDEL: Structural and Dynamical Exploration of Low Density Lipoprotein (LDL)

  • LDL is a natural nanoparticle that mediates the transport of cholesterol in human circulation - it also plays a prominent role in the development of atherosclerosis. The development of new treatment strategies requires a deep understanding of LDL’s molecular structure and function. However, its complex three-dimensional structure, consisting of lipids and protein, has not yet been fully solved. Our aim is not only to describe the structure of LDL, but especially to include its dynamical aspects. We achieve this with an integrative approach that combines various state-of-the-art methods: (cryo)electron microscopy, MD simulations, high-speed atomic force microscopy, X-ray and neutron scattering.
  • Project duration: 2022-2027
  • Funded by: FWF, ANR
  • Collaboration partners: Judith Peters & Tamas Foeldes (ILL, Grenoble, France), Ambroise Desfosses (IBS, Grenoble, France), Peter Hinterdorfer (JKU Linz, Austria).

AoDiSys: Asynchronous Dilution System for industrial manufacturing processes in pharmaceuticals, biotechnology, and material technology

  • This three-year FFG project aims to scientifically support the development, implementation, and validation of the AoDiSys (Asynchronous Dilution System), which is designed for industrial manufacturing processes in pharmaceuticals, biotechnology, and material technology in collaboration with BRAVE Analytics GmbH. AoDiSys enables the integration of the nanoparticle characterization technology OF2i® (OptoFluidic Force Induction) into production plants to improve real-time process feedback and quality control for nanoparticle-based products such as infusions, vaccines, and coatings. This reduces waste, saves resources and energy, and provides new insights into process workflows.
  • Project duration: 2023-2026
  • Funded by: FFG
  • Project leader: Christian Hill (Medical Physics and Biophysics, Med Uni Graz)
  • Project partners: BRAVE Analytics GmbH, Pharmaceutical industry.

Division of Biophysics

Karin Kornmüller 
T: +43 316 385 71695